Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As described below under Item 5.07 of this Current Report on Form 8-K, on January 24, 2023, Health Sciences Acquisitions Corporation 2, a Cayman Islands exempted company (the "Company" or "HSAC2"), convened an extraordinary general meeting of its shareholders (the "Meeting") to consider and vote upon, among other things, the previously announced Business Combination (as defined below) of HSAC Olympus Merger Sub, Inc., a Delaware corporation and a majority-owned subsidiary of HSAC2 ("Merger Sub"), with Orchestra BioMed, Inc., a Delaware corporation ("Orchestra").

At the Meeting, the Company's shareholders approved, among other items, the Orchestra BioMed Holdings, Inc. 2023 Equity Incentive Plan (the "Equity Incentive Plan"). A description of the material terms of the Equity Incentive Plan is included in HSAC2's definitive proxy statement/prospectus filed with the Securities and Exchange Commission (the "SEC") on December 12, 2022 (the "Proxy Statement/Prospectus"), which description is incorporated herein by reference. Such description does not purport to be complete and is qualified in its entirety by reference to the full text of the Equity Incentive Plan, the form of which is attached as Annex D, to the Proxy Statement/Prospectus and is also incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

As previously disclosed in the Current Report on Form 8-K filed on July 5, 2022 by HSAC2 with the SEC, HSAC2 entered into an Agreement and Plan of Merger, dated as of July 4, 2022 (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of July 21, 2022 and Amendment No. 2 to the Agreement and Plan of Merger, dated as of November 21, 2022 (the "Merger Agreement")), with Merger Sub and Orchestra, pursuant to which, among other things, HSAC2 will be domesticated as a Delaware corporation and will be renamed "Orchestra BioMed Holdings, Inc." ("New Orchestra") and, promptly thereafter, Merger Sub will be merged with and into Orchestra with Orchestra surviving the merger as a wholly owned subsidiary of New Orchestra (the "Business Combination").

On August 8, 2022, HSAC2 filed a Registration Statement on Form S-4 (the "Registration Statement"), which includes the Proxy Statement/Prospectus, with the SEC in connection with the Business Combination. On December 16, 2022, the Registration Statement was declared effective by the SEC.

On January 24, 2022, HSAC2 held the Meeting, in connection with the proposals set forth in the Proxy Statement/Prospectus. The Meeting was held at 10:30 a.m. Eastern Time at the offices of Loeb & Loeb LLP at 345 Park Avenue, New York, NY 10154 USA and virtually via live webcast at https://www.virtualshareholdermeeting.com/HSAQ2022SM2.

On December 7, 2022, the record date for the Meeting, there were 11,212,117 ordinary shares, par value $0.0001 per share, of HSAC2 ("HSAC2 Ordinary Shares") outstanding and entitled to vote at the Meeting. At the Meeting, there were 9,777,562 shares voted by proxy or in person, which is 87.20% of the total HSAC2 Ordinary Shares outstanding on the record date for the Meeting and therefore constituted a quorum for the transaction of business.

Summarized below are the results of the matters submitted to a vote at the Meeting. All nine (9) proposals (the "Proposals") were approved by the Company's shareholders.





                                       1





Matter                                                         For       Against    Abstain

        ?    Proposal 1 - The Business Combination          9,442,937     293,625    41,000
             Proposal - To approve by ordinary
             resolution, the transactions contemplated by
             the Merger Agreement, as amended.

        ?    Proposal 2 - The Domestication Proposal - To   9,443,337     293,225    41,000
             approve by special resolution that HSAC2 be
             de-registered in the Cayman Islands pursuant
             to the Amended and Restated Memorandum and
             Articles of Association of HSAC2 and the
             Companies Act (2022 Revision) (As Revised)
             and be registered by way of continuation as
             a corporation in the State of Delaware (the
             "Domestication").


        ?    Proposal 3 - The Charter Approval Proposal -   9,443,337     293,225    41,000
             To approve by special resolution, in
             connection with the Business Combination,
             the replacement of the Amended and Restated
             Memorandum and Articles of Association of
             HSAC2 with the proposed amended and restated
             certificate of incorporation of HSAC2, in
             the form attached to the Proxy
             Statement/Prospectus as Annex B (the
             "Proposed Charter"), to be effective upon
             the consummation of the Domestication.


        ?    Proposal 4 - The Bylaws Approval Proposal -    9,442,337     294,225    41,000
             To approve by special resolution, in
             connection with the Business Combination,
             the bylaws, in the form attached to the
             Proxy Statement/Prospectus as Annex C (the
             "Proposed Bylaws"), to be effective upon
             consummation of the Domestication.

        ?    Proposal 5 - The Advisory Governance
             Proposals - To approve by ordinary
             resolution, on a non-binding advisory basis,
             certain governance provisions contained in
             the Proposed Charter, which were presented
             in accordance with the requirements of the
             SEC as six separate sub-proposals.

        ?    Advisory Governance Proposal A - To increase   7,789,559   1,947,003    41,000
             the total number of authorized shares of all
             classes of capital stock to 350,000,000
             shares, consisting of 340,000,000 authorized
             shares of common stock and 10,000,000
             authorized shares of preferred stock.

        ?    Advisory Governance Proposal B - To provide    8,459,930   1,276,632    41,000
             that the alteration, amendment or repeal of
             certain provisions of the Proposed Charter
             will require the affirmative vote of the
             holders of at least 66-2/3% of the voting
             power of the then-outstanding shares of
             stock entitled to vote thereon, voting
             together as a single class.




                                       2





Matter                                                         For       Against    Abstain

        ?    Advisory Governance Proposal C - To provide    8,459,930   1,276,632    41,000
             that the alteration, amendment or repeal of
             the Proposed Bylaws will require the
             affirmative vote of the holders of at
             least 66-2/3% of the voting power of the
             then-outstanding shares of stock entitled to
             vote thereon, voting together as a single
             class.

        ?    Advisory Governance Proposal D - To provide    8,514,853   1,221,709    41,000
             that stockholders will not be permitted to
             act by written consent in lieu of holding a
             meeting of stockholders.

        ?    Advisory Governance Proposal E - To provide    8,325,943   1,410,619    41,000
             for certain additional changes, including,
             among other things, (i) adopting Delaware as
             the exclusive forum for certain stockholder
             litigation and the federal district courts
             of the United States as the exclusive forum
             for certain other stockholder litigation in
             each case unless New Orchestra expressly
             consents in writing to the selection of an
             alternative forum and (ii) removing certain
             provisions related to HSAC2's status as a
             blank check company that will no longer be
             applicable upon consummation of the Business
             Combination, all of which HSAC2's board of
             directors believe are necessary to
             adequately address the needs of New
             Orchestra after the Business Combination.

        ?    Advisory Governance Proposal F - To change     9,442,937     293,625    41,000
             the post-Business Combination corporate name
             from "Health Sciences Acquisitions
             Corporation 2" to "Orchestra BioMed
             Holdings, Inc.".




                                       3





Matter                                                         For       Against    Abstain

        ?    Proposal 6 - The Nasdaq Proposal - To          9,442,937     293,625    41,000
             approve by ordinary resolution for purposes
             of complying with applicable listing rules
             of the Nasdaq Capital Market, the issuance
             by New Orchestra of shares of common stock,
             par value US$0.0001 per share, to equity
             holders of Orchestra.

        ?    Proposal 7 - The Director Election Proposal
             - To approve by ordinary resolution the
             election of Eric A. Rose, M.D., Jason Aryeh,
             Pamela Y. Connealy, Geoffrey W. Smith, David
             P. Hochman, Darren R. Sherman and Eric
             S. Fain, M.D. to serve staggered terms on
             New Orchestra's board of directors until the
             2023, 2024 and 2025 annual meetings of
             stockholders, as applicable, and until their
             respective successors are duly elected and
             qualified or until their earlier death,
             resignation or removal.

             Eric A. Rose, M.D                              9,705,289      31,273    41,000

             Jason Aryeh                                    9,705,064      31,273    41,225

             Pamela Y. Connealy                             9,705,064      31,273    41,225

             Geoffrey W. Smith                              9,705,064      31,273    41,225

             David P. Hochman                               9,705,064      31,273    41,225

             Darren R. Sherman                              9,705,064      31,273    41,225

             Eric S. Fain, M.D.                             9,705,289      31,273    41,000

        ?    Proposal 8 - The Equity Incentive Plan         8,714,518   1,021,819    41,225
             Proposal - To approve by ordinary resolution
             the Equity Incentive Plan, in the form
             attached to the Proxy Statement/Prospectus
             as Annex D, to be effective upon
             consummation of the Business Combination.

        ?    Proposal 9 - The Adjournment Proposal - To     8,708,143   1,018,419    51,000
             approve by ordinary resolution the
             adjournment of the Meeting by the chairman
             thereof to a later date, if necessary, under
             certain circumstances, including for the
             purpose of soliciting additional proxies in
             favor of the foregoing Proposals, in the
             event HSAC2 does not receive the requisite
             shareholder vote to approve the Proposals.




                                       4


Item 8.01 Other Events



Based on the results of the Meeting, and subject to the satisfaction or waiver of certain other closing conditions as described in the Proxy Statement/Prospectus, the closing date of the Business Combination is anticipated to be in January 2023.

Cautionary Note Regarding Forward-Looking Statements

The statements contained in this Current Report on Form 8-K that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipates," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this report may include, for example, statements about our ability to complete our initial business combination; our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; the delisting of our securities from Nasdaq or an inability to have our securities listed on Nasdaq following a business combination; the potential liquidity and trading of our securities; and the lack of a market for our securities. Factors that can affect future results include, but are not limited to, those discussed under the heading "Risk Factors" and "Management's Discussion and Analysis of Financial Condition" in the Company's filings with the Securities and Exchange Commission. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws and/or if and when management knows or has a reasonable basis on which to conclude that previously disclosed projections are no longer reasonably attainable.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



104       Cover Page Interactive Data File, formatted in Inline Extensible
          Business Reporting Language (iXBRL).




                                       5

© Edgar Online, source Glimpses